{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T23:35:44Z","timestamp":1773099344403,"version":"3.50.1"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.cyto.2015.12.022","type":"journal-article","created":{"date-parts":[[2016,1,5]],"date-time":"2016-01-05T19:40:16Z","timestamp":1452022816000},"page":"52-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Soluble Fas\/FasL ratio as a marker of vasculopathy in children and adolescents with sickle cell disease"],"prefix":"10.1016","volume":"79","author":[{"given":"Amira A.","family":"Adly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eman A.","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nevine G.","family":"Andrawes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai M.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rasha","family":"Eladawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2015.12.022_b0005","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/S0140-6736(04)17192-4","article-title":"Sickle-cell disease","volume":"364","author":"Stuart","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.cyto.2015.12.022_b0010","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1089\/ars.2009.2822","article-title":"Heme degradation and vascular injury","volume":"12","author":"Belcher","year":"2010","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.cyto.2015.12.022_b0015","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1681\/ASN.2002010084","article-title":"Glomerular involvement in adults with sickle cell hemoglobinopathies: prevalence and clinical correlations of progressive renal failure","volume":"17","author":"Guasch","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.cyto.2015.12.022_b0020","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1056\/NEJM199804163381617","article-title":"Circulating endothelial cells in sickle cell anemia","volume":"338","author":"Ortiz","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cyto.2015.12.022_b0025","first-page":"447","article-title":"Tumor necrosis factor induces apoptosis (programmed cell death) in normal endothelial cells in vitro","volume":"138","author":"Robaye","year":"1991","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.cyto.2015.12.022_b0030","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0022-2143(97)90176-1","article-title":"The endothelial biology of sickle cell disease","volume":"129","author":"Hebbel","year":"1997","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.cyto.2015.12.022_b0035","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0092-8674(00)81874-7","article-title":"Apoptosis by death factor","volume":"88","author":"Nagata","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.cyto.2015.12.022_b0040","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1126\/science.7533326","article-title":"The Fas death factor","volume":"267","author":"Nagata","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.cyto.2015.12.022_b0045","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1182\/blood.V91.8.2793.2793_2793_2799","article-title":"Elevation of the serum Fas Ligand in patients with hemophagocytic syndrome and Diamond-Blackfan Anemia","volume":"91","author":"Hasegawa","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.cyto.2015.12.022_b0050","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1359-6101(02)00072-2","article-title":"Non-apoptotic Fas signaling","volume":"14","author":"Wajant","year":"2003","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.cyto.2015.12.022_b0055","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/00000658-200003000-00010","article-title":"Fas and Fas-Ligand expression in human pancreatic cancer","volume":"231","author":"Kornmann","year":"2000","journal-title":"Ann. Surg."},{"key":"10.1016\/j.cyto.2015.12.022_b0060","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/FJC.0b013e318198fe60","article-title":"Role of Fas\/FasL in vascular cell apoptosis","volume":"53","author":"Stoneman","year":"2009","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.cyto.2015.12.022_b0065","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1172\/JCI3248","article-title":"Apoptosis mediated by fas but not tumor necrosis factor receptor 1 prevents chronic disease in mice infected with murine cytomegalovirus","volume":"102","author":"Fleck","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cyto.2015.12.022_b0070","first-page":"1013","article-title":"Sickle cell disease in childhood: Part I. Laboratory diagnosis, pathophysiology and health maintenance","volume":"62","author":"Wethers","year":"2000","journal-title":"Am. Fam. Phys."},{"key":"10.1016\/j.cyto.2015.12.022_b0075","series-title":"Manual of Pediatric Hematology and Oncology","first-page":"221","article-title":"Hemoglobinopathies","author":"Kwiatkowski","year":"2011"},{"key":"10.1016\/j.cyto.2015.12.022_b0080","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJM199107043250103","article-title":"Pain in sickle cell disease. Rates and risk factors","volume":"325","author":"Platt","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cyto.2015.12.022_b0085","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.3324\/haematol.2009.008938","article-title":"CURAMA study group. Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease","volume":"94","author":"van Beers","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.cyto.2015.12.022_b0090","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jpeds.2011.07.018","article-title":"Markers of severe vaso-occlusive painful episode frequency in children and adolescents with sickle cell anemia","volume":"160","author":"Darbari","year":"2012","journal-title":"J. Pediatr."},{"key":"10.1016\/j.cyto.2015.12.022_b0095","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.3324\/haematol.2011.047852","article-title":"Elevated liver iron concentration is a marker of increased morbidity in patients with \u03b2 thalassemia intermedia","volume":"96","author":"Musallam","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.cyto.2015.12.022_b0100","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.2337\/diacare.27.2007.S79","article-title":"American diabetes association. Nephropathy in diabetes","volume":"27","author":"Molitch","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cyto.2015.12.022_b0105","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1542\/peds.2007-0730","article-title":"Prevalence and risk factors of elevated pulmonary artery pressures in children with sickle cell disease","volume":"121","author":"Pashankar","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.cyto.2015.12.022_b0110","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/blood-2010-11-319152","article-title":"Thalassemia Clinical Research Network. Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network report","volume":"118","author":"Morris","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cyto.2015.12.022_b0115","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1378\/chest.127.5.1523","article-title":"Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia","volume":"127","author":"Aessopos","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.cyto.2015.12.022_b0120","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3928\/00904481-20080501-07","article-title":"Sickle cell disease: new insights into pathophysiology and treatment","volume":"37","author":"Inati","year":"2008","journal-title":"Pediatr. Ann."},{"key":"10.1016\/j.cyto.2015.12.022_b0125","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(10)61029-X","article-title":"Sickle cell diseae","volume":"376","author":"Rees","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cyto.2015.12.022_b0130","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1182\/blood-2002-10-3313","article-title":"Transgenic sickle mice have vascular inflammation","volume":"101","author":"Belcher","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.cyto.2015.12.022_b0135","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1084\/jem.185.8.1511","article-title":"Differential induction of apoptosis by Fas-Fas Ligand interactions in human monocytes and macrophages","volume":"185","author":"Kiener","year":"1997","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cyto.2015.12.022_b0140","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/77521","article-title":"Fas\/FADD-mediated activation of a specific program of inflammatory gene expression in vascular smooth muscle cells","volume":"6","author":"Schaub","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.cyto.2015.12.022_b0145","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1161\/01.ATV.0000250616.26308.d7","article-title":"Increased soluble Fas plasma levels in subjects at high cardiovascular risk","volume":"27","author":"Blanco-Colio","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.cyto.2015.12.022_b0150","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1056\/NEJM199711273372203","article-title":"Circulating activated endothelial cells in sickle cell anemia","volume":"337","author":"Solovey","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cyto.2015.12.022_b0155","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/(SICI)1096-8652(200004)63:4<205::AID-AJH8>3.0.CO;2-8","article-title":"Renal abnormalities in sickle cell disease","volume":"63","author":"Ataga","year":"2000","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.cyto.2015.12.022_b0160","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.bcmd.2014.07.018","article-title":"Cystatin C: a useful marker of glomerulopathy in sickle cell disease?","volume":"54","author":"Asnani","year":"2015","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.cyto.2015.12.022_b0165","first-page":"26","article-title":"Microalbuminuria represents a feature of advanced renal disease in patients with sickle cell nephropathy","volume":"4","author":"Ackoundou-N\u2019 Guesson","year":"2006","journal-title":"Ann. Ib. Postgrad. Med."},{"key":"10.1016\/j.cyto.2015.12.022_b0170","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s00467-010-1536-8","article-title":"Prevalence and clinical correlates of microalbuminuria in children with sickle cell disease","volume":"25","author":"Becton","year":"2010","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.cyto.2015.12.022_b0175","doi-asserted-by":"crossref","first-page":"240173","DOI":"10.1155\/2012\/240173","article-title":"Prevalence and correlates of microalbuminuriain children with sickle cell anemia: experience in a Tertiary Health Facility in Enugu, Nigeria","volume":"2012","author":"Eke","year":"2012","journal-title":"Int. J. Nephrol."},{"key":"10.1016\/j.cyto.2015.12.022_b0180","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000045642","article-title":"Fas-Fas Ligand system in the peripheral blood of patients with renal diseases","volume":"85","author":"Sato","year":"2000","journal-title":"Nephron"},{"key":"10.1016\/j.cyto.2015.12.022_b0185","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.cca.2012.07.025","article-title":"The sFas\/sFasL ratio as a novel marker of inflammation in children with chronic kidney disease","volume":"414","author":"Musia\u0142","year":"2012","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cyto.2015.12.022_b0190","doi-asserted-by":"crossref","first-page":"7584","DOI":"10.4049\/jimmunol.173.12.7584","article-title":"Fas death receptor signaling represses monocyte numbers and macrophage activation in vivo","volume":"173","author":"Brown","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.cyto.2015.12.022_b0195","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.4049\/jimmunol.170.12.6209","article-title":"Fas (CD95) induces proinflammatory cytokine responses by human monocytes and monocyte-derived macrophages","volume":"170","author":"Park","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.cyto.2015.12.022_b0200","doi-asserted-by":"crossref","unstructured":"C.B. Almeida, F.G. Pereira, L. Irene Metze, S. Saad, F. Costa, N. Conran, Induction of caspase-independent apoptosis by sickle cell disease (SCD) serum in non-SCD leukocytes. 50th ASH annual meeting and exposition 2008. Poster Session: Hemoglobinopathies, Excluding Thalassemia Poster II; 2475.","DOI":"10.1182\/blood.V112.11.2475.2475"},{"key":"10.1016\/j.cyto.2015.12.022_b0205","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/asheducation-2005.1.51","article-title":"Cardiopulmonary complications of sickle cell disease: role of nitric oxide and hemolytic anemia","author":"Gladwin","year":"2005","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"10.1016\/j.cyto.2015.12.022_b0210","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1161\/01.ATV.17.10.2200","article-title":"Fas is expressed in human atherosclerotic intima and promotes apoptosis of cytokine-primed human vascular smooth muscle cells","volume":"17","author":"Geng","year":"1997","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.cyto.2015.12.022_b0215","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/01.STR.0000114876.51656.7A","article-title":"NF-kB activation and Fas ligand overexpression in blood and plaques of patients with carotid atherosclerosis","volume":"35","author":"Martin-Ventura","year":"2004","journal-title":"Stroke"},{"key":"10.1016\/j.cyto.2015.12.022_b0220","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S1050-1738(99)00006-7","article-title":"Negative regulation of inflammation by Fas ligand expression on the vascular endothelium","volume":"9","author":"Walsh","year":"1999","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.cyto.2015.12.022_b0225","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nm0498-415","article-title":"TNF-regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation","volume":"4","author":"Sata","year":"1998","journal-title":"Nat. Med."},{"key":"10.1016\/j.cyto.2015.12.022_b0230","first-page":"29","article-title":"The relationship of serum soluble Fas Ligand (sFasL) level with the extent of coronary artery disease","volume":"211","author":"Sahinarslan","year":"2012","journal-title":"Int. J. Angiol."},{"key":"10.1016\/j.cyto.2015.12.022_b0235","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1161\/01.CIR.102.8.915","article-title":"Involvement of CD95\/Apo1\/Fas in cell death after myocardial ischemia","volume":"102","author":"Jeremias","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.cyto.2015.12.022_b0240","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1097\/00004872-200205000-00024","article-title":"Soluble Fas ligand and atherosclerosis in hypertensive patients","volume":"20","author":"Okura","year":"2000","journal-title":"J. Hypertens."},{"key":"10.1016\/j.cyto.2015.12.022_b0245","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s10157-009-0261-8","article-title":"Soluble Fas: a useful marker of inflammation and cardiovascular diseases in uremic patients","volume":"14","author":"El-Agroudy","year":"2010","journal-title":"Clin. Exp. Nephrol."},{"key":"10.1016\/j.cyto.2015.12.022_b0250","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.hoc.2005.07.007","article-title":"Pulmonary hypertension in sickle cell disesa: mechanisms, diagnosis and management","volume":"19","author":"Castro","year":"2005","journal-title":"Hematol. Oncol. Clin. North. Am."},{"key":"10.1016\/j.cyto.2015.12.022_b0255","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood.V96.7.2451","article-title":"Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion","volume":"96","author":"Belcher","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.cyto.2015.12.022_b0260","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/00062752-200203000-00003","article-title":"Sickle cell vaso-occlusion: multistep and multicellular paradigm","volume":"9","author":"Frenette","year":"2002","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.cyto.2015.12.022_b0265","first-page":"102","article-title":"Erythrocyte adhesion in sickle cell disease","volume":"2","author":"Parise","year":"2003","journal-title":"Curr. Hematol. Rep."},{"key":"10.1016\/j.cyto.2015.12.022_b0270","doi-asserted-by":"crossref","first-page":"620","DOI":"10.2174\/156652408786241447","article-title":"Nitric oxide and arginine dysregulation: a novel pathway to pulmonary hypertension in hemolytic disorders","volume":"8","author":"Morris","year":"2008","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.cyto.2015.12.022_b0275","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3109\/03630260008993134","article-title":"Determinants of red cell survival and erythropoietic activity in patients with sickle cell anemia in the steady state","volume":"24","author":"Ballas","year":"2000","journal-title":"Hemoglobin"},{"key":"10.1016\/j.cyto.2015.12.022_b0280","doi-asserted-by":"crossref","first-page":"695","DOI":"10.3109\/00016349609065729","article-title":"Increased release of tumor necrosis factor-alpha and interleukin-6 in women with the syndrome of hemolysis, elevated liver enzymes, and low platelet count","volume":"75","author":"Haeger","year":"1996","journal-title":"Acta Obstet. Gynecol. Scand."},{"issue":"34","key":"10.1016\/j.cyto.2015.12.022_b0285","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1590\/S0100-879X2001001000011","article-title":"Interleukin 8 as a vaso-occlusive marker in Brazilian patients with sickle cell disease","volume":"2001","author":"Goncalves","year":"2001","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.cyto.2015.12.022_b0290","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1172\/JCI9225","article-title":"Hypoxia\/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice","volume":"106","author":"Kaul","year":"2000","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cyto.2015.12.022_b0295","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/10245332.2000.11746536","article-title":"The role of inflammation and leukocytes in the pathogenesis of sickle cell disease; haemoglobinopathy","volume":"5","author":"Wun","year":"2001","journal-title":"Hematology"},{"key":"10.1016\/j.cyto.2015.12.022_b0300","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0037-1963(01)90031-9","article-title":"Pharmacological induction of fetal hemoglobin in sickle cell disease and beta-thalassemia","volume":"38","author":"Atweh","year":"2001","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.cyto.2015.12.022_b0305","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on frequency of painful crises in sickle cell anemia","volume":"332","author":"Charache","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cyto.2015.12.022_b0310","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1001\/jama.289.13.1645","article-title":"Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment","volume":"289","author":"Steinberg","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.cyto.2015.12.022_b0315","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/00005792-199611000-00002","article-title":"Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive \u201cswitching\u201d agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia","volume":"75","author":"Charache","year":"1996","journal-title":"Medicine"},{"key":"10.1016\/j.cyto.2015.12.022_b0320","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/S0140-6736(11)60355-3","article-title":"Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)","volume":"377","author":"Wang","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.cyto.2015.12.022_b0325","doi-asserted-by":"crossref","first-page":"a011783","DOI":"10.1101\/cshperspect.a011783","article-title":"The natural history of sickle cell disease","volume":"3","author":"Serjeant","year":"2013","journal-title":"Cold Spring Harb. Perspect. Med."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466615301368?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466615301368?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,13]],"date-time":"2020-09-13T15:52:04Z","timestamp":1600012324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466615301368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":65,"alternative-id":["S1043466615301368"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2015.12.022","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Soluble Fas\/FasL ratio as a marker of vasculopathy in children and adolescents with sickle cell disease","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2015.12.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}